Frontiers in Oncology · 2022 · 38 citations · 19 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyApoptosis In CancerApoptosis ResistanceCancer Cell SignalingEpithelial-mesenchymal TransitionLung CancerMalignant NeoplasmsCancer Cell Proliferation InhibitionCell Viability AssaysEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPi3k SignalingPi3k-akt Signaling Pathway
Objective To explore the impacts of AE (aloe-emodin) in gefitinib-resistant NSCLC (non-small cell lung cancer) cells and the corresponding mechanism. Methods PC9 and PC9-GR cells were cultured and treated by gefitinib, AE, or the combination of the two drugs. Then, viability, apoptosis, migration and invasion of cells were investigated using CCK-8, TUNEL, wound healing assay, and transwell assay, respectively. Female BALB/c nude mice were employed for the establishment of xenograft tumor models to examine the role of AE in tumor growth. Results PC9-GR cells showed reduced apoptosis and enhanced cell viability, migration and invasion upon treatment by gefitinib, compared with PC9 cells. E-cahherin in PC9-GR cells was down-regulated, while Vimentin, Snail2 (or Slug) and Twist1 in PC9-GR cells were up-regulated, compared with PC9 cells. Meanwhile, treatment by a combination of gefitinib and AE significantly strengthened apoptosis of PC9-GR cells, while attenuated their migration and invasion, compared with the control group or treatment by gefitinib or AE alone. WB results showed that AE could reverse EMT and activation of PI3K/AKT signalling pathway in PC9-GR cells. In vivo experiments showed that tumor growth and EMT of PC9-GR cells were dramatically repressed after treatment by a combination of AE and gefitinib. Additionally, the use of SC97 (a PI3K/Akt pathway activator) could counteract the effects of AE in gefitinib-resistant PC9 cells. Conclusions AE could enhance the gefitinib sensitivity of PC9-GR cells and reverse EMT by blocking PI3K/Akt/TWIS1 signal pathway.
19
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Sana Raoof, Iain J. Mulford, Heidie Frisco Cabanos et al. · Oncogene · 2019 · 213 citations · Full text
Medicine, Cancer Biology, Oncology +11
Guohua Zhou, Zhang Fangli, Guo Yu et al. · Biomedicine & Pharmacotherapy · 2016 · 120 citations
Medicine, Cell Biology, Oncology +14